High-performance proteins at the speed of mRNA.
Boost's Rapid Antigen Deployment (RAD™) pathogen-family platforms enable antigens, vaccines, and monoclonal antibodies against globally important pathogens — engineered for safety, efficacy, rapid response and scale-up, low-cost, stability, and the potential for terminal sterilization and intranasal administration.
Our lead SARS-CoV-2 program is in Phase 1, with data mid-2026.
Backed by the Best
The world's leading pandemic-preparedness and biomedical-research institutions — including the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institutes of Health / National Institute of Allergy and Infectious Disease (NIH/NIAID), and the Center for the Biomedical Advanced Research and Development Authority (BARDA) — fund and support Boost’s work developing leading-edge vaccines and monoclonal antibodies.
The company is also supported by a group of dedicated and knowledgable investors.
Open to opportunity.
We're building a company that responds to global health needs with safety, efficacy, speed, and cost in mind. If that's a vision you share — as an investor, partner, or collaborator — let's talk.